Phase I clinical trial of the combination of eribulin and everolimus in patients with metastatic triple-negative breast cancer

BACKGROUND: Alteration of the PI3K/AKT/mTOR pathway is a common genomic abnormality detected in triple-negative breast cancer (TNBC). Everolimus acts synergistically with eribulin in TNBC cell lines and xenograft models. This phase I trial was designed to test the safety and tolerability of combinin...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Jin Sun, Yost, Susan E., Blanchard, Suzette, Schmolze, Daniel, Yin, Hongwei Holly, Pillai, Raju, Robinson, Kim, Tang, Aileen, Martinez, Norma, Portnow, Jana, Wen, Wei, Yim, John H., Brauer, Heather Ann, Ren, Yuqi, Luu, Thehang, Mortimer, Joanne, Yuan, Yuan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6839083/
https://www.ncbi.nlm.nih.gov/pubmed/31703728
http://dx.doi.org/10.1186/s13058-019-1202-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6839083/
https://www.ncbi.nlm.nih.gov/pubmed/31703728
http://dx.doi.org/10.1186/s13058-019-1202-4

Ejemplares similares